SOPHiA GENETICS S.A.

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, GEHC has a market cap of 38.4B. Regarding current trading prices, SOPH is priced at $4.84, while GEHC trades at $83.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas GEHC's P/E ratio is 18.51. In terms of profitability, SOPH's ROE is -0.94%, compared to GEHC's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GEHC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, VEEV has a market cap of 29.6B. Regarding current trading prices, SOPH is priced at $4.84, while VEEV trades at $182.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas VEEV's P/E ratio is 35.15. In terms of profitability, SOPH's ROE is -0.94%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SOPH is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VEEV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SOPH is priced at $4.84, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to GEHCV's ROE of +0.21%. Regarding short-term risk, SOPH is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check GEHCV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BTSGU has a market cap of 24.7B. Regarding current trading prices, SOPH is priced at $4.84, while BTSGU trades at $135.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to BTSGU's ROE of +0.08%. Regarding short-term risk, SOPH is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSGU's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, TEM has a market cap of 10.1B. Regarding current trading prices, SOPH is priced at $4.84, while TEM trades at $59.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas TEM's P/E ratio is -201.28. In terms of profitability, SOPH's ROE is -0.94%, compared to TEM's ROE of -0.68%. Regarding short-term risk, SOPH is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TEM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SOPH is priced at $4.84, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SOPH's ROE is -0.94%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SOPH is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SGFY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BTSG has a market cap of 7.4B. Regarding current trading prices, SOPH is priced at $4.84, while BTSG trades at $40.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BTSG's P/E ratio is 76.04. In terms of profitability, SOPH's ROE is -0.94%, compared to BTSG's ROE of +0.08%. Regarding short-term risk, SOPH is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BTSG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HQY has a market cap of 6.8B. Regarding current trading prices, SOPH is priced at $4.84, while HQY trades at $78.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HQY's P/E ratio is 36.19. In terms of profitability, SOPH's ROE is -0.94%, compared to HQY's ROE of +0.09%. Regarding short-term risk, SOPH is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HQY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SOPH is priced at $4.84, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas RCM's P/E ratio is -102.21. In terms of profitability, SOPH's ROE is -0.94%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SOPH is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check RCM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, DOCS has a market cap of 4.8B. Regarding current trading prices, SOPH is priced at $4.84, while DOCS trades at $25.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas DOCS's P/E ratio is 21.48. In terms of profitability, SOPH's ROE is -0.94%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, SOPH is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check DOCS's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SOPH is priced at $4.84, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SOPH's ROE is -0.94%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SOPH is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ONEM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HNGE has a market cap of 3.3B. Regarding current trading prices, SOPH is priced at $4.84, while HNGE trades at $41.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HNGE's P/E ratio is -5.32. In terms of profitability, SOPH's ROE is -0.94%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, SOPH is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HNGE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PRVA has a market cap of 2.7B. Regarding current trading prices, SOPH is priced at $4.84, while PRVA trades at $21.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PRVA's P/E ratio is 157.07. In terms of profitability, SOPH's ROE is -0.94%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PRVA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, TXG has a market cap of 2.4B. Regarding current trading prices, SOPH is priced at $4.84, while TXG trades at $19.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas TXG's P/E ratio is -53.94. In terms of profitability, SOPH's ROE is -0.94%, compared to TXG's ROE of -0.06%. Regarding short-term risk, SOPH is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TXG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, WGS has a market cap of 2.4B. Regarding current trading prices, SOPH is priced at $4.84, while WGS trades at $90.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas WGS's P/E ratio is 746.00. In terms of profitability, SOPH's ROE is -0.94%, compared to WGS's ROE of +0.01%. Regarding short-term risk, SOPH is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check WGS's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SOPH is priced at $4.84, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PINC's P/E ratio is 166.24. In terms of profitability, SOPH's ROE is -0.94%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PINC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HTFL has a market cap of 2.1B. Regarding current trading prices, SOPH is priced at $4.84, while HTFL trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HTFL's P/E ratio is -16.73. In terms of profitability, SOPH's ROE is -0.94%, compared to HTFL's ROE of +0.18%. Regarding short-term risk, SOPH is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HTFL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, OMCL has a market cap of 1.8B. Regarding current trading prices, SOPH is priced at $4.84, while OMCL trades at $38.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas OMCL's P/E ratio is 1006.50. In terms of profitability, SOPH's ROE is -0.94%, compared to OMCL's ROE of +0.00%. Regarding short-term risk, SOPH is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OMCL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, SOPH is priced at $4.84, while PGNY trades at $20.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PGNY's P/E ratio is 33.84. In terms of profitability, SOPH's ROE is -0.94%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, SOPH is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check PGNY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $4.84, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SOPH's ROE is -0.94%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check NXGN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $4.84, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SOPH's ROE is -0.94%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AGTI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CERT has a market cap of 1B. Regarding current trading prices, SOPH is priced at $4.84, while CERT trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CERT's P/E ratio is 92.29. In terms of profitability, SOPH's ROE is -0.94%, compared to CERT's ROE of +0.01%. Regarding short-term risk, SOPH is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CERT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SDGR has a market cap of 849.4M. Regarding current trading prices, SOPH is priced at $4.84, while SDGR trades at $11.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SDGR's P/E ratio is -4.80. In terms of profitability, SOPH's ROE is -0.94%, compared to SDGR's ROE of -0.48%. Regarding short-term risk, SOPH is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SDGR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, TDOC has a market cap of 841.2M. Regarding current trading prices, SOPH is priced at $4.84, while TDOC trades at $4.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas TDOC's P/E ratio is -3.59. In terms of profitability, SOPH's ROE is -0.94%, compared to TDOC's ROE of -0.16%. Regarding short-term risk, SOPH is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check TDOC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, GDRX has a market cap of 838.2M. Regarding current trading prices, SOPH is priced at $4.84, while GDRX trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas GDRX's P/E ratio is 30.88. In terms of profitability, SOPH's ROE is -0.94%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, SOPH is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check GDRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CCLDO has a market cap of 806M. Regarding current trading prices, SOPH is priced at $4.84, while CCLDO trades at $25.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, SOPH is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDO's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PHR has a market cap of 765.6M. Regarding current trading prices, SOPH is priced at $4.84, while PHR trades at $12.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PHR's P/E ratio is -141.11. In terms of profitability, SOPH's ROE is -0.94%, compared to PHR's ROE of -0.02%. Regarding short-term risk, SOPH is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PHR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, OMDA has a market cap of 672.9M. Regarding current trading prices, SOPH is priced at $4.84, while OMDA trades at $11.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas OMDA's P/E ratio is -25.26. In terms of profitability, SOPH's ROE is -0.94%, compared to OMDA's ROE of -0.16%. Regarding short-term risk, SOPH is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OMDA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SOPH is priced at $4.84, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to MPLN-WT's ROE of +31.86%. Regarding short-term risk, SOPH is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN-WT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HSTM has a market cap of 603.7M. Regarding current trading prices, SOPH is priced at $4.84, while HSTM trades at $20.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HSTM's P/E ratio is 29.93. In terms of profitability, SOPH's ROE is -0.94%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, SOPH is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check HSTM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, NUTX has a market cap of 601.9M. Regarding current trading prices, SOPH is priced at $4.84, while NUTX trades at $103.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas NUTX's P/E ratio is 4.93. In terms of profitability, SOPH's ROE is -0.94%, compared to NUTX's ROE of +0.46%. Regarding short-term risk, SOPH is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check NUTX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SOPH is priced at $4.84, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SOPH's ROE is -0.94%, compared to ACCD's ROE of -0.39%. Regarding short-term risk, SOPH is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACCD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SOPH is priced at $4.84, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SOPH's ROE is -0.94%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHCR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SY has a market cap of 414.9M. Regarding current trading prices, SOPH is priced at $4.84, while SY trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SY's P/E ratio is -3.02. In terms of profitability, SOPH's ROE is -0.94%, compared to SY's ROE of -0.42%. Regarding short-term risk, SOPH is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SY's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $4.84, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SOPH's ROE is -0.94%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $4.84, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SOPH's ROE is -0.94%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLGCW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CTEV has a market cap of 385M. Regarding current trading prices, SOPH is priced at $4.84, while CTEV trades at $23.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CTEV's P/E ratio is -1.11. In terms of profitability, SOPH's ROE is -0.94%, compared to CTEV's ROE of +31.86%. Regarding short-term risk, SOPH is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CTEV's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SOPH is priced at $4.84, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SOPH's ROE is -0.94%, compared to MPLN's ROE of +31.86%. Regarding short-term risk, SOPH is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MPLN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CARL has a market cap of 339.6M. Regarding current trading prices, SOPH is priced at $4.84, while CARL trades at $12.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CARL's P/E ratio is -12.90. In terms of profitability, SOPH's ROE is -0.94%, compared to CARL's ROE of +0.83%. Regarding short-term risk, SOPH is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CARL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, EVH has a market cap of 323.6M. Regarding current trading prices, SOPH is priced at $4.84, while EVH trades at $2.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas EVH's P/E ratio is -1.78. In terms of profitability, SOPH's ROE is -0.94%, compared to EVH's ROE of -0.14%. Regarding short-term risk, SOPH is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check EVH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, NRC has a market cap of 309.7M. Regarding current trading prices, SOPH is priced at $4.84, while NRC trades at $12.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas NRC's P/E ratio is 27.34. In terms of profitability, SOPH's ROE is -0.94%, compared to NRC's ROE of +0.59%. Regarding short-term risk, SOPH is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check NRC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, TBRG has a market cap of 304.4M. Regarding current trading prices, SOPH is priced at $4.84, while TBRG trades at $19.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas TBRG's P/E ratio is 84.50. In terms of profitability, SOPH's ROE is -0.94%, compared to TBRG's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TBRG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SOPH is priced at $4.84, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SOPH's ROE is -0.94%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SOPH is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check TRHC's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SPOK has a market cap of 279.3M. Regarding current trading prices, SOPH is priced at $4.84, while SPOK trades at $13.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SPOK's P/E ratio is 16.95. In terms of profitability, SOPH's ROE is -0.94%, compared to SPOK's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SPOK's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SOPH is priced at $4.84, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SMFR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to SMFR's ROE of +0.13%. Regarding short-term risk, SOPH is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SMFR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SLP has a market cap of 234.9M. Regarding current trading prices, SOPH is priced at $4.84, while SLP trades at $12.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SLP's P/E ratio is -3.64. In terms of profitability, SOPH's ROE is -0.94%, compared to SLP's ROE of -0.45%. Regarding short-term risk, SOPH is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SLP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, DH has a market cap of 156M. Regarding current trading prices, SOPH is priced at $4.84, while DH trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas DH's P/E ratio is -0.88. In terms of profitability, SOPH's ROE is -0.94%, compared to DH's ROE of -0.56%. Regarding short-term risk, SOPH is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check DH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, OPRX has a market cap of 152.9M. Regarding current trading prices, SOPH is priced at $4.84, while OPRX trades at $8.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas OPRX's P/E ratio is 820.00. In terms of profitability, SOPH's ROE is -0.94%, compared to OPRX's ROE of +0.00%. Regarding short-term risk, SOPH is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OPRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SOPH is priced at $4.84, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SOPH's ROE is -0.94%, compared to CPSI's ROE of -0.05%. Regarding short-term risk, SOPH is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check CPSI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HCAT has a market cap of 126.6M. Regarding current trading prices, SOPH is priced at $4.84, while HCAT trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HCAT's P/E ratio is -1.13. In terms of profitability, SOPH's ROE is -0.94%, compared to HCAT's ROE of -0.30%. Regarding short-term risk, SOPH is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCAT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SOPH is priced at $4.84, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SOPH's ROE is -0.94%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SOPH is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AUGX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CCLD has a market cap of 102.2M. Regarding current trading prices, SOPH is priced at $4.84, while CCLD trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CCLD's P/E ratio is 34.43. In terms of profitability, SOPH's ROE is -0.94%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, SOPH is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, AMWL has a market cap of 91M. Regarding current trading prices, SOPH is priced at $4.84, while AMWL trades at $5.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas AMWL's P/E ratio is -0.92. In terms of profitability, SOPH's ROE is -0.94%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, SOPH is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AMWL's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, FORA has a market cap of 64.6M. Regarding current trading prices, SOPH is priced at $4.84, while FORA trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas FORA's P/E ratio is -104.00. In terms of profitability, SOPH's ROE is -0.94%, compared to FORA's ROE of -0.03%. Regarding short-term risk, SOPH is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check FORA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SOPH is priced at $4.84, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, SOPH is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CCLDP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BEAT has a market cap of 48.6M. Regarding current trading prices, SOPH is priced at $4.84, while BEAT trades at $1.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BEAT's P/E ratio is -2.14. In terms of profitability, SOPH's ROE is -0.94%, compared to BEAT's ROE of -5.99%. Regarding short-term risk, SOPH is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BEAT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SOPH is priced at $4.84, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SOPH's ROE is -0.94%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SOPH is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SNCE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, EUDA has a market cap of 34.1M. Regarding current trading prices, SOPH is priced at $4.84, while EUDA trades at $0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas EUDA's P/E ratio is 45.12. In terms of profitability, SOPH's ROE is -0.94%, compared to EUDA's ROE of -0.09%. Regarding short-term risk, SOPH is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check EUDA's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SOPH is priced at $4.84, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SOPH's ROE is -0.94%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SOPH is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check AKLI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SOPH is priced at $4.84, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SOPH's ROE is -0.94%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SOPH is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHLT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SOPH is priced at $4.84, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.94%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check SHCRW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SOPH is priced at $4.84, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas STRM's P/E ratio is -2.40. In terms of profitability, SOPH's ROE is -0.94%, compared to STRM's ROE of -0.50%. Regarding short-term risk, SOPH is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check STRM's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SOPH is priced at $4.84, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SOPH's ROE is -0.94%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SOPH is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check RNLX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SOPH is priced at $4.84, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.94%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ONMD has a market cap of 21.4M. Regarding current trading prices, SOPH is priced at $4.84, while ONMD trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ONMD's P/E ratio is -10.89. In terms of profitability, SOPH's ROE is -0.94%, compared to ONMD's ROE of +0.20%. Regarding short-term risk, SOPH is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ONMD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SOPH is priced at $4.84, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SOPH's ROE is -0.94%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SOPH is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BBLN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SOPH is priced at $4.84, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -0.94%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SOPH is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ETAO's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SOPH is priced at $4.84, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.94%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SOPH is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HLTH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, SCNX has a market cap of 6.2M. Regarding current trading prices, SOPH is priced at $4.84, while SCNX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas SCNX's P/E ratio is 0.53. In terms of profitability, SOPH's ROE is -0.94%, compared to SCNX's ROE of -0.26%. Regarding short-term risk, SOPH is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check SCNX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MGRX has a market cap of 5.9M. Regarding current trading prices, SOPH is priced at $4.84, while MGRX trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MGRX's P/E ratio is -0.19. In terms of profitability, SOPH's ROE is -0.94%, compared to MGRX's ROE of -1.15%. Regarding short-term risk, SOPH is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check MGRX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, VSEE has a market cap of 5.5M. Regarding current trading prices, SOPH is priced at $4.84, while VSEE trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas VSEE's P/E ratio is 0.74. In terms of profitability, SOPH's ROE is -0.94%, compared to VSEE's ROE of +3.37%. Regarding short-term risk, SOPH is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check VSEE's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $4.84, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas UPH's P/E ratio is -0.07. In terms of profitability, SOPH's ROE is -0.94%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check UPH's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BFRG has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $4.84, while BFRG trades at $0.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BFRG's P/E ratio is -0.79. In terms of profitability, SOPH's ROE is -0.94%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, SOPH is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRG's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BEATW has a market cap of 4.7M. Regarding current trading prices, SOPH is priced at $4.84, while BEATW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BEATW's P/E ratio is -0.27. In terms of profitability, SOPH's ROE is -0.94%, compared to BEATW's ROE of -5.99%. Regarding short-term risk, SOPH is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check BEATW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $4.84, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -0.94%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEAR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $4.84, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.94%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check PEARW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, EUDAW has a market cap of 2.9M. Regarding current trading prices, SOPH is priced at $4.84, while EUDAW trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to EUDAW's ROE of -0.09%. Regarding short-term risk, SOPH is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check EUDAW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SOPH is priced at $4.84, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -0.94%, compared to OTRK's ROE of -2.04%. Regarding short-term risk, SOPH is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check OTRK's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, BFRGW has a market cap of 2M. Regarding current trading prices, SOPH is priced at $4.84, while BFRGW trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, SOPH is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check BFRGW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, WORX has a market cap of 1.7M. Regarding current trading prices, SOPH is priced at $4.84, while WORX trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas WORX's P/E ratio is -0.49. In terms of profitability, SOPH's ROE is -0.94%, compared to WORX's ROE of -0.72%. Regarding short-term risk, SOPH is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check WORX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $4.84, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CMAX's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CMAX's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ACON has a market cap of 1.5M. Regarding current trading prices, SOPH is priced at $4.84, while ACON trades at $2.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ACON's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to ACON's ROE of -0.68%. Regarding short-term risk, SOPH is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check ACON's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $4.84, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWZ's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, VSEEW has a market cap of 1.2M. Regarding current trading prices, SOPH is priced at $4.84, while VSEEW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to VSEEW's ROE of +3.37%. Regarding short-term risk, SOPH is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check VSEEW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ZCMD has a market cap of 1M. Regarding current trading prices, SOPH is priced at $4.84, while ZCMD trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ZCMD's P/E ratio is -1.18. In terms of profitability, SOPH's ROE is -0.94%, compared to ZCMD's ROE of -0.08%. Regarding short-term risk, SOPH is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ZCMD's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, HCTI has a market cap of 573.6K. Regarding current trading prices, SOPH is priced at $4.84, while HCTI trades at $6.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas HCTI's P/E ratio is -0.07. In terms of profitability, SOPH's ROE is -0.94%, compared to HCTI's ROE of -1.13%. Regarding short-term risk, SOPH is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check HCTI's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MSPR has a market cap of 556.5K. Regarding current trading prices, SOPH is priced at $4.84, while MSPR trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MSPR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, SOPH is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPR's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SOPH is priced at $4.84, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SOPH is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check MSPRZ's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, WGSWW has a market cap of 416.2K. Regarding current trading prices, SOPH is priced at $4.84, while WGSWW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to WGSWW's ROE of +0.01%. Regarding short-term risk, SOPH is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check WGSWW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $4.84, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas KERN's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -0.94%, compared to KERN's ROE of -0.13%. Regarding short-term risk, SOPH is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERN's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $4.84, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.94%, compared to KERNW's ROE of -0.13%. Regarding short-term risk, SOPH is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check KERNW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SOPH is priced at $4.84, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check LIFWW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, SOPH is priced at $4.84, while OTRKP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -0.94%, compared to OTRKP's ROE of -2.04%. Regarding short-term risk, SOPH is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check OTRKP's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SOPH is priced at $4.84, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check CMAXW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ACONW has a market cap of 21.8K. Regarding current trading prices, SOPH is priced at $4.84, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ACONW's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -0.94%, compared to ACONW's ROE of -0.68%. Regarding short-term risk, SOPH is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ACONW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, MSPRW has a market cap of 5.5K. Regarding current trading prices, SOPH is priced at $4.84, while MSPRW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, SOPH is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check MSPRW's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, SOPH is priced at $4.84, while ICCT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas ICCT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to ICCT's ROE of +2.42%. Regarding short-term risk, SOPH is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check ICCT's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, SOPH is priced at $4.84, while FOXO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas FOXO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to FOXO's ROE of -0.80%. Regarding short-term risk, SOPH is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for SOPH.Check FOXO's competition here

SOPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 322.3M. In comparison, UTRS has a market cap of 888. Regarding current trading prices, SOPH is priced at $4.84, while UTRS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -4.24, whereas UTRS's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -0.94%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, SOPH is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for SOPH.Check UTRS's competition here